Monopathogenic vs multipathogenic explanations of pemphigus pathophysiology
暂无分享,去创建一个
E. Sprecher | M. Pittelkow | N. Cirillo | M. Carrozzo | R. Gniadecki | M. Hertl | A. Ahmed | A. Sinha | C. Pincelli | E. Schmidt | S. Grando | M. Dmochowski | F. Caux | M. J. López-Zabalza | R. Lotti | A. Alonso | Abdul Razzaq Ahmed
[1] C. Kelly,et al. Serum and salivary IgG and IgA antibodies to desmoglein 3 in mucosal pemphigus vulgaris , 2016, The British journal of dermatology.
[2] W. Robinson,et al. Multiplexed autoantigen microarrays identify HLA as a key driver of anti-desmoglein and -non-desmoglein reactivities in pemphigus , 2016, Proceedings of the National Academy of Sciences.
[3] Y. Boo,et al. Antimelanogenic effects of luteolin 7‐sulfate isolated from Phyllospadix iwatensis Makino , 2016, The British journal of dermatology.
[4] Y. Tokura,et al. Epitope analysis of antidesmoglein 1 autoantibodies from patients with pemphigus foliaceus across different activity stages , 2016, The British journal of dermatology.
[5] J. Waschke,et al. Loss of Desmoglein Binding Is Not Sufficient for Keratinocyte Dissociation in Pemphigus. , 2015, The Journal of investigative dermatology.
[6] M. Pittelkow,et al. Pseudo pemphigus phenotypes in mice with inactivated desmoglein 3: further insight to the complexity of pemphigus pathophysiology. , 2015, The American journal of pathology.
[7] Yumay Chen,et al. Pemphigus vulgaris antibodies target the mitochondrial nicotinic acetylcholine receptors that protect keratinocytes from apoptolysis. , 2015, International immunopharmacology.
[8] Yumay Chen,et al. Critical Role of the Neonatal Fc Receptor (FcRn) in the Pathogenic Action of Antimitochondrial Autoantibodies Synergizing with Anti-desmoglein Autoantibodies in Pemphigus Vulgaris* , 2015, The Journal of Biological Chemistry.
[9] A. Sinha,et al. Detailed profiling of anti-desmoglein autoantibodies identifies anti-Dsg1 reactivity as a key driver of disease activity and clinical expression in pemphigus vulgaris , 2015, Autoimmunity.
[10] E. Müller,et al. Preclinical Studies Identify Non-Apoptotic Low-Level Caspase-3 as Therapeutic Target in Pemphigus Vulgaris , 2015, PloS one.
[11] J. Rathmell,et al. A spontaneous deletion within the desmoglein 3 extracellular domain of mice results in hypomorphic protein expression, immunodeficiency, and a wasting disease phenotype. , 2015, The American journal of pathology.
[12] R. Holmdahl,et al. Pathogenic IgG Antibodies against Desmoglein 3 in Pemphigus Vulgaris Are Regulated by HLA-DRB1*04:02–Restricted T Cells , 2014, The Journal of Immunology.
[13] M. Jonkman,et al. No evidence of apoptotic cells in pemphigus acantholysis. , 2014, The Journal of investigative dermatology.
[14] D. Zillikens,et al. Specific immunoadsorption of pathogenic autoantibodies in pemphigus requires the entire ectodomains of desmogleins , 2014, Experimental dermatology.
[15] N. Cirillo,et al. Pemphigus vulgaris autoimmune globulin induces Src-dependent tyrosine-phosphorylation of plakophilin 3 and its detachment from desmoglein 3 , 2014, Autoimmunity.
[16] K. Amber,et al. Autoreactive T cells in the immune pathogenesis of pemphigus vulgaris , 2013, Experimental dermatology.
[17] O. Sarig,et al. Desmoglein 1 deficiency results in severe dermatitis, multiple allergies and metabolic wasting , 2013, Nature Genetics.
[18] Sally E. Ward,et al. Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis , 2013, mAbs.
[19] Yumay Chen,et al. Mechanisms of Mitochondrial Damage in Keratinocytes by Pemphigus Vulgaris Antibodies* , 2013, The Journal of Biological Chemistry.
[20] M. Camilleri,et al. Pemphigus Vulgaris Autoantibody Profiling by Proteomic Technique , 2013, PloS one.
[21] K. Sardana,et al. Is there an emergent need to modify the desmoglein compensation theory in pemphigus on the basis of Dsg ELISA data and alternative pathogenic mechanisms? , 2013, The British journal of dermatology.
[22] G. Harms,et al. Peptide-mediated desmoglein 3 crosslinking prevents pemphigus vulgaris autoantibody-induced skin blistering. , 2013, The Journal of clinical investigation.
[23] Eva Hartlieb,et al. Desmoglein 2 Is Less Important than Desmoglein 3 for Keratinocyte Cohesion , 2013, PloS one.
[24] Y. Aoyama,et al. Detection of antibodies against the non‐calcium‐dependent epitopes of desmoglein 3 in pemphigus vulgaris and their pathogenic significance , 2012, The British journal of dermatology.
[25] A. Marconi,et al. Apoptotic pathways in the pathogenesis of pemphigus: targets for new therapies. , 2012, Current pharmaceutical biotechnology.
[26] S. Rosset,et al. Population-specific association between a polymorphic variant in ST18, encoding a pro-apoptotic molecule, and pemphigus vulgaris. , 2012, The Journal of investigative dermatology.
[27] H. Koga,et al. Epitope spreading is rarely found in pemphigus vulgaris by large-scale longitudinal study using desmoglein 2-based swapped molecules. , 2012, The Journal of investigative dermatology.
[28] A. Mulder,et al. Low‐dose rituximab is effective in pemphigus , 2012, The British journal of dermatology.
[29] A. Sinha. Constructing immunoprofiles to deconstruct disease complexity in pemphigus , 2012, Autoimmunity.
[30] D. Garrod,et al. An adult passive transfer mouse model to study desmoglein 3 signaling in pemphigus vulgaris , 2011, The Journal of investigative dermatology.
[31] A. Shimizu,et al. Pathogenic relevance of IgG and IgM antibodies against desmoglein 3 in blister formation in pemphigus vulgaris. , 2011, The American journal of pathology.
[32] R. Ober,et al. Neonatal Fc Receptor Blockade by Fc Engineering Ameliorates Arthritis in a Murine Model , 2011, The Journal of Immunology.
[33] G. M. Rosa,et al. ACE inhibitors can induce circulating antibodies directed to antigens of the superficial epidermal cells , 2011, Archives of Dermatological Research.
[34] S. Grando. Pemphigus autoimmunity: Hypotheses and realities , 2011, Autoimmunity.
[35] D. Molina,et al. New targets of pemphigus vulgaris antibodies identified by protein array technology , 2011, Experimental dermatology.
[36] R. Eming,et al. IgG autoantibodies against desmocollin 3 in pemphigus sera induce loss of keratinocyte adhesion. , 2011, The American journal of pathology.
[37] M. Amagai,et al. Autoimmunity to desmocollin 3 in pemphigus vulgaris. , 2010, The American journal of pathology.
[38] D. Siegel,et al. Homologous regions of autoantibody heavy chain complementarity-determining region 3 (H-CDR3) in patients with pemphigus cause pathogenicity. , 2010, The Journal of clinical investigation.
[39] E. Bröcker,et al. Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients , 2010, Experimental dermatology.
[40] Y. Aoyama. What’s new in i.v. immunoglobulin therapy and pemphigus: High‐dose i.v. immunoglobulin therapy and its mode of action for treatment of pemphigus , 2010, The Journal of dermatology.
[41] W. Uter,et al. Clinical activity of pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3. , 2010, Clinical immunology.
[42] M. Chua,et al. p38MAPK Signaling and Desmoglein-3 Internalization Are Linked Events in Pemphigus Acantholysis* , 2010, The Journal of Biological Chemistry.
[43] K. Green,et al. Desmosomes at a glance , 2009, Journal of Cell Science.
[44] A. Peserico,et al. Detection of Autoantibodies against Recombinant Desmoglein 1 and 3 Molecules in Patients with Pemphigus vulgaris: Correlation with Disease Extent at the Time of Diagnosis and during Follow-Up , 2009, Clinical & developmental immunology.
[45] S. Grando,et al. Antimitochondrial Autoantibodies in Pemphigus Vulgaris , 2009, The Journal of Biological Chemistry.
[46] D. Siegel,et al. Update on the cloning of monoclonal anti-desmoglein antibodies from human pemphigus patients: implications for targeted therapy. , 2009, Veterinary dermatology.
[47] B. Pelacho,et al. An imbalance in Akt/mTOR is involved in the apoptotic and acantholytic processes in a mouse model of pemphigus vulgaris , 2009, Experimental dermatology.
[48] M. Pittelkow,et al. Apoptolysis: a novel mechanism of skin blistering in pemphigus vulgaris linking the apoptotic pathways to basal cell shrinkage and suprabasal acantholysis , 2009, Experimental dermatology.
[49] J. Waschke,et al. Apoptosis in pemphigus. , 2009, Autoimmunity reviews.
[50] M. Chua,et al. Biphasic Activation of p38MAPK Suggests That Apoptosis Is a Downstream Event in Pemphigus Acantholysis* , 2009, Journal of Biological Chemistry.
[51] H. Mouquet,et al. ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus. , 2009, Archives of dermatology.
[52] Clifford M. Babbey,et al. Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells. , 2008, Molecular biology of the cell.
[53] Jiangli Chen,et al. Loss of desmocollin 3 in mice leads to epidermal blistering , 2008, Journal of Cell Science.
[54] T. Nishikawa,et al. Anti‐desmoglein IgG autoantibodies in patients with pemphigus in remission , 2008, Journal of the European Academy of Dermatology and Venereology : JEADV.
[55] D. Zillikens,et al. Neonatal Fc receptor deficiency protects from tissue injury in experimental epidermolysis bullosa acquisita , 2008, Journal of Molecular Medicine.
[56] S. Grando,et al. Differential Coupling of M1 Muscarinic and α7 Nicotinic Receptors to Inhibition of Pemphigus Acantholysis* , 2008, Journal of Biological Chemistry.
[57] M. Lanza,et al. The most widespread desmosomal cadherin, desmoglein 2, is a novel target of caspase 3‐mediated apoptotic machinery , 2008, Journal of cellular biochemistry.
[58] J. Narbutt,et al. Circulating pemphigus autoantibodies in healthy relatives of pemphigus patients: coincidental phenomenon with a risk of disease development? , 2007, Archives of Dermatological Research.
[59] S. Grando,et al. Desmoglein Versus Non-desmoglein Signaling in Pemphigus Acantholysis , 2007, Journal of Biological Chemistry.
[60] A. Bitonti,et al. Amelioration of Experimental Autoimmune Myasthenia Gravis in Rats by Neonatal FcR Blockade , 2007, The Journal of Immunology.
[61] N. Cirillo,et al. Caspase‐dependent cleavage of desmoglein 1 depends on the apoptotic stimulus , 2007, The British journal of dermatology.
[62] B. Qaqish,et al. Prevalence of anti-desmoglein-3 antibodies in endemic regions of Fogo selvagem in Brazil. , 2006, The Journal of investigative dermatology.
[63] P. Hu,et al. p38MAPK inhibition prevents disease in pemphigus vulgaris mice , 2006, Proceedings of the National Academy of Sciences.
[64] J. Sanches,et al. Clinical and serological follow‐up studies of endemic pemphigus foliaceus (fogo selvagem) in Western Parana, Brazil (2001–2002) , 2006, The British journal of dermatology.
[65] J. Bystryn,et al. Sensitivity of indirect immunofluorescence and ELISA in detecting intercellular antibodies in endemic pemphigus foliaceus (Fogo Selvagem) , 2006, International journal of dermatology.
[66] Vinod K. Sharma,et al. Evaluation of desmoglein enzyme‐linked immunosorbent assay (ELISA) in Indian patients with pemphigus vulgaris , 2006, International journal of dermatology.
[67] G. Elgart,et al. Antibodies against desmoglein 1 in healthy subjects in endemic and nonendemic areas of pemphigus foliaceus (fogo selvagem) in Peru , 2006, International journal of dermatology.
[68] S. Grando,et al. Cholinergic control of epidermal cohesion , 2006, Experimental dermatology.
[69] J. Bystryn,et al. A novel explanation for acantholysis in pemphigus vulgaris: the basal cell shrinkage hypothesis. , 2006, Journal of the American Academy of Dermatology.
[70] S. Morrison,et al. Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life. , 2006, Molecular immunology.
[71] M. David,et al. Apoptotic mechanism in pemphigus autoimmunoglobulins-induced acantholysis—possible involvement of the EGF receptor , 2006, Autoimmunity.
[72] S. Grando,et al. Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in Pemphigus. , 2005, The American journal of pathology.
[73] D. Roopenian,et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. , 2005, The Journal of clinical investigation.
[74] T. Krieg,et al. Anti‐CD20 monoclonal antibody (rituximab) in the treatment of pemphigus , 2005, The British journal of dermatology.
[75] R. Bergman,et al. A comparison of anti‐desmoglein antibodies and indirect immunofluorescence in the serodiagnosis of pemphigus vulgaris , 2005, International journal of dermatology.
[76] Y. Shirakata,et al. In vitro keratinocyte dissociation assay for evaluation of the pathogenicity of anti-desmoglein 3 IgG autoantibodies in pemphigus vulgaris. , 2005, The Journal of investigative dermatology.
[77] J. Balthasar,et al. Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions. , 2005, Journal of pharmaceutical sciences.
[78] Y. Hanakawa,et al. Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display. , 2005, The Journal of clinical investigation.
[79] B. Qaqish,et al. Anti-desmoglein-1 antibodies in onchocerciasis, leishmaniasis and Chagas disease suggest a possible etiological link to Fogo selvagem. , 2004, The Journal of investigative dermatology.
[80] S. Akilesh,et al. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. , 2004, The Journal of clinical investigation.
[81] M. Feinmesser,et al. Possible apoptotic mechanism in epidermal cell acantholysis induced by pemphigus vulgaris autoimmunoglobulins , 2004, Apoptosis.
[82] T. Pozzan,et al. Human keratinocyte ATP2C1 localizes to the Golgi and controls Golgi Ca2+ stores. , 2003, The Journal of investigative dermatology.
[83] P. Amerio,et al. Urokinase plasminogen activator mRNA is induced by IL‐1α and TNF‐α in in vitro acantholysis , 2003, Experimental dermatology.
[84] J. Bystryn,et al. Antibodies to desmoglein 1 and 3, and the clinical phenotype of pemphigus vulgaris. , 2003, Journal of the American Academy of Dermatology.
[85] T. Nishikawa,et al. Induction of Pemphigus Phenotype by a Mouse Monoclonal Antibody Against the Amino-Terminal Adhesive Interface of Desmoglein 3 1 , 2003, The Journal of Immunology.
[86] Y. Kitajima. Mechanisms of desmosome assembly and disassembly , 2002, Clinical and experimental dermatology.
[87] C. Massone,et al. Allergic contact dermatitis from thiurams with pemphigus‐like autoantibodies , 2002, Contact dermatitis.
[88] L. Diaz,et al. A subset of pemphigus foliaceus patients exhibits pathogenic autoantibodies against both desmoglein-1 and desmoglein-3. , 2002, The Journal of investigative dermatology.
[89] Yusuke Suzuki,et al. FcRn-mediated transcytosis of immunoglobulin G in human renal proximal tubular epithelial cells. , 2002, American journal of physiology. Renal physiology.
[90] M. Seishima,et al. Increased antibody levels to desmogleins 1 and 3 after administration of carbamazepine , 2001, Clinical and experimental dermatology.
[91] D. Zillikens,et al. IgG, IgA and IgE autoantibodies against the ectodomain of desmoglein 3 in active pemphigus vulgaris , 2001, The British journal of dermatology.
[92] M. Simionescu,et al. Expression of functionally active FcRn and the differentiated bidirectional transport of IgG in human placental endothelial cells. , 2001, Human immunology.
[93] S. Grando. Autoimmunity to Keratinocyte Acetylcholine Receptors in Pemphigus , 2000, Dermatology.
[94] M. Pittelkow,et al. Antibodies against keratinocyte antigens other than desmogleins 1 and 3 can induce pemphigus vulgaris-like lesions. , 2000, The Journal of clinical investigation.
[95] S. Grando,et al. Novel human alpha9 acetylcholine receptor regulating keratinocyte adhesion is targeted by Pemphigus vulgaris autoimmunity. , 2000, The American journal of pathology.
[96] J. Sulkes,et al. The distribution of pemphigus vulgaris‐IgG subclasses and their reactivity with desmoglein 3 and 1 in pemphigus patients and their first‐degree relatives , 2000, The British journal of dermatology.
[97] R. Hoffmann,et al. The Prevalence of Antibodies against Desmoglein 1 in Endemic Pemphigus Foliaceus in Brazil , 2000 .
[98] A. Monaco,et al. Hailey–Hailey disease is caused by mutations in ATP2C1 encoding a novel Ca2+ pump , 2000 .
[99] T. Nishikawa,et al. Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus. , 2000, The Journal of clinical investigation.
[100] M. Udey,et al. Pemphigus--diseases of antidesmosomal autoimmunity. , 1999, JAMA.
[101] D. Kelsell,et al. N-terminal deletion in a desmosomal cadherin causes the autosomal dominant skin disease striate palmoplantar keratoderma. , 1999, Human molecular genetics.
[102] Zhi Hong Wang,et al. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. , 1999, The Journal of clinical investigation.
[103] T. Nishikawa,et al. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. , 1999, Journal of the American Academy of Dermatology.
[104] P. Amerio,et al. In vitro C3 mRNA Expression in Pemphigus Vulgaris: Complement Activation is Increased by IL-1α and TNF-α , 1999 .
[105] T. Nishikawa,et al. Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice. , 1998, The Journal of clinical investigation.
[106] T. X. Lee,et al. The pathophysiological significance of nondesmoglein targets of pemphigus autoimmunity. Development of antibodies against keratinocyte cholinergic receptors in patients with pemphigus vulgaris and pemphigus foliaceus. , 1998, Archives of dermatology.
[107] E. Fuchs,et al. Mice expressing a mutant desmosomal cadherin exhibit abnormalities in desmosomes, proliferation, and epidermal differentiation , 1996, The Journal of cell biology.
[108] T. Nishikawa,et al. Antigen-specific immunoadsorption of pathogenic autoantibodies in pemphigus foliaceus. , 1995, The Journal of investigative dermatology.
[109] T. Nishikawa,et al. Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. , 1994, The Journal of clinical investigation.
[110] M. Amagai,et al. Extracellular domain of pemphigus vulgaris antigen (desmoglein 3) mediates weak homophilic adhesion. , 1994, The Journal of investigative dermatology.
[111] M. Amagai,et al. Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. , 1992, The Journal of clinical investigation.
[112] M. Black,et al. The distribution of immunoglobulins and the C3 component of complement in multiple biopsies from the uninvolved and perilesional skin in pemphigus , 1986, Clinical and experimental dermatology.
[113] L. Borradori,et al. A new light on an old disease: adhesion signaling in pemphigus vulgaris. , 2014, The Journal of investigative dermatology.
[114] F. Sera,et al. Are clinical phenotype and autoantibody profile always concordant in pemphigus? A study in a cohort of pemphigus patients. , 2013, European journal of dermatology : EJD.
[115] R. Yumoto,et al. Megalin/cubilin-mediated uptake of FITC-labeled IgG by OK kidney epithelial cells. , 2011, Drug metabolism and pharmacokinetics.
[116] E. Alpsoy,et al. Immunopathologic features of pemphigus in the east Mediterranean region of Turkey: a prospective study. , 2010, Skinmed.
[117] Vinod K. Sharma,et al. Comparison of enzyme-linked immunosorbent assay test with immunoblot assay in the diagnosis of pemphigus in Indian patients. , 2010, Indian journal of dermatology, venereology and leprology.
[118] H. Wajant,et al. Apoptosis is not required for acantholysis in pemphigus vulgaris. , 2009, American journal of physiology. Cell physiology.
[119] L. Diaz,et al. Inhibition of pemphigus vulgaris by targeting of the CD40-CD154 co-stimulatory pathway: a step toward antigen-specific therapy? , 2006, The Journal of investigative dermatology.
[120] K. Wolff,et al. Expression of FcRn, the MHC class I-related receptor for IgG, in human keratinocytes. , 2005, The Journal of investigative dermatology.
[121] A. Marconi,et al. Fas ligand in pemphigus sera induces keratinocyte apoptosis through the activation of caspase-8. , 2003, The Journal of investigative dermatology.
[122] T. Mauro,et al. Mutations in ATP2C1, encoding a calcium pump, cause Hailey-Hailey disease , 2000, Nature Genetics.
[123] P. Amerio,et al. In Vitro and In Vivo Expression of Interleukin-1α and Tumor Necrosis Factor-α mRNA in Pemphigus Vulgaris: Interleukin-1α and Tumor Necrosis Factor-α are Involved in Acantholysis , 2000 .
[124] S. Brenner,et al. Circulating pemphigus IgG in families of patients with pemphigus: comparison of indirect immunofluorescence, direct immunofluorescence, and immunoblotting. , 1997, Journal of the American Academy of Dermatology.
[125] T. Hashimoto,et al. Pemphigus IgG, but not bullous pemphigoid IgG, causes a transient increase in intracellular calcium and inositol 1,4,5-triphosphate in DJM-1 cells, a squamous cell carcinoma line. , 1995, The Journal of investigative dermatology.